Felbamate levels in patients with epilepsy

Cynthia L. Harden, Rosario Trifiletti, Henn Kutt

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined. The purpose of the present study was to determine if FBM levels obtained at routine office visits correlated with side effects reported by patients. We determined FBM levels by high-pressure liquid chromatography (HPLC) of 46 epilepsy patient plasma specimens (41 patients) and assessed medication toxicity and seizure frequency by a questionnaire. Thirty-six patients were treated with other antiepileptic drugs (AEDs); concomitant AED levels not in ranges believed to cause toxicity. FBM levels ranged from 9 to 134 μg/ml, and were divided into three groups for analysis, resulting in low-range (9-36 μg/ml), midrange (37-54 μg/ml), and high- level (44-134 μg/ml) groups. Anorexia and complaints of severe side effects were reported significantly more often in the high-level group as compared with the low- and midrange groups. Significantly more patients in the high- level group (10/13) reported decreased seizure frequency, as compared with 12 of 30 of patients in the low- and midrange groups combined. FBM levels correlated linearly with doses overall, but most closely in FBM monotherapy patients.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
Issue number3
StatePublished - Mar 1996
Externally publishedYes


  • Antiepileptic drug levels
  • Epilepsy
  • Felbamate


Dive into the research topics of 'Felbamate levels in patients with epilepsy'. Together they form a unique fingerprint.

Cite this